StockNews.AI
BLRX
StockNews.AI
148 days

BioLineRx to Report 2024 Annual Results on March 31, 2025

1. BioLineRx will report financial results on March 31, 2025. 2. CEO Philip Serlin will host the conference call. 3. BioLineRx focuses on oncology and rare diseases. 4. APHEXDA® is its first approved product for stem cell mobilization. 5. The company emphasizes its end-to-end expertise in drug development.

Earnings
-8.38%Current Return
VS
+1.84%S&P 500
$3.5803/24 07:07 AM EDTEvent Start
$3.2803/25 01:33 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

The upcoming financial results and conference call may stabilize stock, as investors await performance insights.

How important is it?

The financial report could shape short-term investor sentiment, but lacks extraordinary news.

Why Short Term?

Financial reports typically have immediate effects on stock prices, similar to past performance disclosures.

Related Companies

AYRMYGLBS
Management to Hold Conference Call at 8:30 a.m. EDT , /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. A replay of the call will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until April 2, 2025; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally. About BioLineRx BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding Asia) and Gloria Biosciences (in Asia). BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs, manufacturing and commercialization to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside. Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.  and events. CONTACTS: United States      Irina Koffler LifeSci Advisors, LLC[email protected] IsraelMoran MeirLifeSci Advisors, LLC[email protected] Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg  SOURCE BioLineRx Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News